The effects of Rosuvastatin on serum CTRP 9 and ghrelin levels in patients with coronary artery disease
- VernacularTitle:瑞舒伐他汀对冠心病患者血清CTRP9及ghrelin水平的影响
- Author:
Jianfeng WANG
- Publication Type:Journal Article
- Keywords:
coronary artery disease;
rosuvastatin;
C1q/TNF-related protein;
glrelin
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(1):113-115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association of serum levels of C1 q/TNF-related protein (CTRP 9) and ghrelin with coronary artery disease, and observe the effects of Rosuvastain on serum CTRP 9 and ghrelin. Method Serum levels of CTRP 9 and ghrelin in 120 patients with coronary artery disease and 80 healthy controls were measured. Then 120 patients were randomly divided into control group and Rosuvastatin group. Patients in both groups were given regular treatment. In addition, patients in Rosuvastatin group were treated with Rosuvastatin (10 mg/d) for 4 weeks. Serum levels of CTRP 9 and ghrelin in the two groups were examined before and after treatment. Results Serum levels of CTRP 9 and ghrelin were significantly decreased in patients with coronary artery disease compared with those in controls (P<0.05). Logistic regression analysis revealed that reduced levels of serum CTRP 9 and ghrelin were independent risk factors of coronary artery disease. After 4 weeks of treatment with Rosuvastatin, serum levels of CTRP 9 and ghrelin were significantly increased (P<0.05). However, no significant differences of serum CTRP 9 and ghrelin were found in control group before and after regular treatment (P>0.05). Conclusion Serum levels of CTRP 9 and ghrelin are significantly decreased in patients with coronary artery disease and they are independent protective factors of coronary artery disease. Rosuvastatin may improve the levels of CTRP 9 and ghrelin for patients with coronary artery disease.
